PROPHYLACTIC TREATMENT OF DEPRESSION IN CANCER PATIENTS

癌症患者抑郁症的预防性治疗

• 批准号: 7951260
• 负责人: ELANA FARACE
• 金额: $ 0.05万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951260
• 关键词: Cancer Patient; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Disease Progression; Face; Funding; Grant; Institution; Moods; Paroxetine; Patients; Placebos; Primary Brain Neoplasms; Prophylactic treatment; Quality of life; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; depression; depressive symptoms

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to determine if patients with primary brain tumors who are treated with paroxetine will have fewer depressive symptoms at three months than patients treated with a placebo. Secondary objective will test whether an improvement in mood relates to a corresponding improvement in quality of life, even in the face of disease progression.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目的是确定接受帕罗西汀治疗的原发性脑肿瘤患者在三个月时的抑郁症状少于接受安慰剂治疗的患者。次要目标将测试情绪的改善是否与疾病进展的相应改善生活质量改善有关。